GUILHERME NADER MARTA
Projetos de Pesquisa
Unidades Organizacionais
LIM/55 - Laboratório de Urologia, Hospital das Clínicas, Faculdade de Medicina
8 resultados
Resultados de Busca
Agora exibindo 1 - 8 de 8
bookPart Agentes alquilantes e compostos relacionados(2021) MARTA, Guilherme Nader; CHAMMAS, Roger- Outcomes and Prognostic Factors in a Large Cohort of Hospitalized Cancer Patients With COVID-19(2021) MARTA, Guilherme Nader; BONADIO, Renata Colombo; SEJAS, Odeli Nicole Encinas; WATARAI, Gabriel; MACHADO, Maria Cecilia Mathias; FRASSON, Lorena Teixeira; MONIZ, Camila Motta Venchiarutti; ITO, Raquel Keiko de Luca; PEIXOTO, Driele; HOFF, Camilla Oliveira; ANASTACIO, Veruska Menegatti; JR, Ulysses Ribeiro; PEREIRA, Juliana; ROCHA, Vanderson; ABDALA, Edson; ESTEVEZ-DIZ, Maria Del Pilar; HOFF, Paulo M.PURPOSE Patients with cancer are at increased risk for unfavorable outcomes from COVID-19. Knowledge about the outcome determinants of severe acute respiratory syndrome coronavirus 2 infection in this population is essential for risk stratification and definition of appropriate management. Our objective was to evaluate prognostic factors for all-cause mortality in patients diagnosed with both cancer and COVID-19. METHODS All consecutive patients with cancer hospitalized at our institution with COVID-19 were included. Electronic medical records were reviewed for clinical and laboratory characteristics potentially associated with outcomes. RESULTS Five hundred seventy-six consecutive patients with cancer and COVID-19 were included in the present study. An overall in-hospital mortality rate of 49.3% was demonstrated. Clinical factors associated with increased risk of death because of COVID-19 were age over 65 years, Eastern Cooperative Oncology Group performance status > 0 zero, best supportive care, primary lung cancer, and the presence of lung metastases. Laboratory findings associated with a higher risk of unfavorable outcomes were neutrophilia, lymphopenia, and elevated levels of D-dimer, creatinine, C-reactive protein, or AST. CONCLUSION A high mortality rate in patients with cancer who were diagnosed with COVID-19 was demonstrated in the present study, emphasizing the need for close surveillance in this group of patients, especially in those with unfavorable prognostic characteristics. (C) 2021 by American Society of Clinical Oncology
conferenceObject Trends in breast cancer mortality in Brazil - a 14-year registry-based study(2021) MARTA, Guilherme Nader; TESTA, Laura; GUINDALINI, Rodrigo Santa Cruz; MARTA, Gustavo Nader; DIZ, Maria Del Pilar Estevez; HOFF, Paulo M.- Stage-dependent prognostic value of systemic inflammatory biomarkers in early triple-negative breast cancer (TNBC)(2021) MARTA, G. Nader; TIECHER, R. Dahmer; VICENTINI, M. F. Batistuzzo; DORNELLAS, A.; HOFF, P. M.; TESTA, L.
- Deep learning algorithm performance in mammography screening: A systematic review and meta-analysis.(2021) ROELA, Rosimeire Aparecida; VALENTE, Gabriel Vansuita; SHIMIZU, Carlos; LOPEZ, Rossana Veronica Mendoza; TUCUNDUVA, Tatiana Cardoso de Mello; FOLGUEIRA, Guilherme Koike; KATAYAMA, Maria Lucia Hirata; PETRINI, Daniel Gustavo Pellacani; NOVAES, Guilherme Apolinario Silva; SERIO, Pedro Adolpho de Menezes Pacheco; MARTA, Guilherme Nader; SAMESHIMA, Koichi; FOLGUEIRA, Maria A. A. Koike
- Final results of CA209-9JC: A phase II study of first-line nivolumab in patients with advanced cutaneous squamous cell carcinoma(2021) MUNHOZ, R. Ramella; CAMARGO, V. P. de; MARTA, G. Nader; QUEIROZ, M. M.; CURY-MARTINS, J.; NARDO, M.; CHAUL-BARBOSA, C.; RICCI, H.; MATTOS, M. R. de; MENEZES, T. A. F. de; MACHADO, G. U. D. C.; BERTOLLI, E.; BARROS, M.; FRANKE, F. A.; FERREIRA, F. D. O.; FEHER, O.; CASTRO JR., G. de
bookPart Prefácio(2021) BONADIO, Renata Rodrigues da Cunha Colombo; MARTA, Guilherme Nader; MOTA, José Maurício Segundo Correia; CASTRO JUNIOR, Gilberto de; HOFF, Paulo Marcelo Gehm- Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma(2021) MARTA, Guilherme Nader; FONSECA, Leonardo G. da; BRAGHIROLI, Maria Ignez; MOURA, Fernando; HOFF, Paulo M.; SABBAGA, JorgeOBJECTIVES: To evaluate the efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC). METHODS: We analyzed data from a cohort of patients with advanced HCC treated using systemic treatment according to the local institutional protocol. Patients were divided into two groups, Group A, individuals <70 years of age, and Group B, individuals 70 years of age or older at the time of treatment initiation. Efficacy, measured based on overall survival (OS) and time to treatment failure (TTF), and toxicity were compared between groups. RESULTS: A total of 238 patients with advanced HCC who received sorafenib between 2007 and 2018 were evaluated. The median age for Group A was 59.1 years and that for Group B 73.6 years. The major prognostic characteristics were balanced between the groups. There were no significant differences in OS between Group A (8.0 months, 95%Cl 6.34-9.3) and Group B (9.0 months, 95%CI 5.38-12.62), p=0.433, or in TTF between Group A (3.0 months, 95%CI 2.39-3.60) and Group B (3.0 months, 95%CI 1.68-4.32), p=0.936. There were no significant differences between Groups A and B with respect to the incidence of adverse events or treatment discontinuation because of toxicity. CONCLUSION: Efficacy and safety of sorafenib did not differ significantly between younger and older patients with HCC. Our data suggest that age alone should not restrict clinical decision-making for patients with advanced HCC.